- Apr 2, 2009
- 5,171
- 13,288
- 67
http://www.eurekalert.org/pub_releases/2010-10/uom-eum100110.php
http://tobaccocontrol.bmj.com/content/19/5/e1.abstract
Citing a lack of scientific evidence, drug industry funded consultants (including three members of FDA's TPSAC: Hatsukami, Henningfield, Benowitz) wrote a recently published article advocating additional and urgent research to prompt the FDA to vastly increase the drug industry's share of the nicotine market by taking it away from cigarettes (via mandatory reductions in nicotine in cigarettes), which also would create a huge untaxed and unregulated cigarette black market, and would cause many smokers to inhale more smoke and increase cigarette consumption (due to nicotine compensation).
While the FDA has rejected/ignored previous requests to dismiss these (and another) TPSAC member due to financial conflicts of interest, I think it will be difficult for the FDA to continue ignoring this blatant financial conflict of interest whereby TPSAC members who receive funding from drug companies then urge the FDA to financially benefit drug companies at the expense of tobacco companies.
Attached is the full text of the article.View attachment 20042
http://tobaccocontrol.bmj.com/content/19/5/e1.abstract
Citing a lack of scientific evidence, drug industry funded consultants (including three members of FDA's TPSAC: Hatsukami, Henningfield, Benowitz) wrote a recently published article advocating additional and urgent research to prompt the FDA to vastly increase the drug industry's share of the nicotine market by taking it away from cigarettes (via mandatory reductions in nicotine in cigarettes), which also would create a huge untaxed and unregulated cigarette black market, and would cause many smokers to inhale more smoke and increase cigarette consumption (due to nicotine compensation).
While the FDA has rejected/ignored previous requests to dismiss these (and another) TPSAC member due to financial conflicts of interest, I think it will be difficult for the FDA to continue ignoring this blatant financial conflict of interest whereby TPSAC members who receive funding from drug companies then urge the FDA to financially benefit drug companies at the expense of tobacco companies.
Attached is the full text of the article.View attachment 20042